Omeros Corp (OMER)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

201 ELLIOTT AVENUE WEST SEATTLE, WA 98119

Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform, which is designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company's lead PharmacoSurgery product candidate, OMS103HP, is in two Phase 3 clinical programs to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament reconstruction surgery, and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its product candidates also include OMS302 for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201 for use during urological surgery, including uroendoscopic procedures of the bladder, ureter, urethra, and other urinary tract structures. The company's pre-clinical developmental programs comprise MASP-2 program, in which it is developing antibody therapies to treat disorders caused by complement activated inflammation; cartilage protective program to treat cartilage disorders, such as osteoarthritis and rheumatoid arthritis; and Phosphodiesterase 10 program for the treatment of schizophrenia; GPCR program to treat a series of CNS disorders. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

Data as of 2020-05-30
Market Cap811.119 Million Shares Outstanding54.511 Million Avg 30-day Volume481.54 Thousand
P/E Ratio Dividend Yield EPS-1.74
Price/Sales7.143 Price cash flow ratio Price free cash flow ratio-14.6
Book Value-2.42 Price to Tangible Book-6.26 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.157965
BETA1.86362 52-week High/Low20.92 / 8.5 Stddev0.20045
View SEC Filings from OMER instead.

View recent insider trading info

Funds Holding OMER (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OMER BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

5 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SPIEGELMAN DANIEL K

  • Director
0 2020-05-27 0

CABLE THOMAS J.

35,067 2020-05-13 4

ZUMWALT KURT

  • Director
998 2020-04-01 2

HANISH ARNOLD C

  • Director
0 2020-03-23 1

HOOD LEROY E. MD PHD

69,390 2020-03-13 3

DEMOPULOS GREGORY A MD CHIARMAN, CEO & PRESIDENT

0 2020-03-01 1

JACOBSEN MICHAEL A VP FINANCE AND CAO

0 2020-03-01 1

CANCELMO PETER B VP, GEN. COUNSEL & CORP. SEC.

0 2020-03-01 3

DEMOPULOS PETER A MD

  • Director
352,898 2019-12-14 2

KELBON MARCIA S. VP PATENT AND GENERAL COUNSEL

  • Officer
210,645 2019-06-07 1

ASPIRI RAY

  • Director
0 2019-06-07 1

SHAH RAJIV

  • Director
0 2019-06-07 1

BUMOL THOMAS F.

  • Director
0 2019-02-09 0

TRIPET JEAN-PHILIPPE

  • Director
0 2011-05-27 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CABLE THOMAS J.

2020-05-13 M 5,000 $5.92 a 40,067 35,067.00 direct

CABLE THOMAS J.

2020-05-13 M 5,000 d 0 35,067.00 direct

CABLE THOMAS J.

2020-05-13 S 5,000 $14.40 d 35,067 35,067.00 direct yes

Elevate your investments